DnB Asset Management’s BridgeBio Pharma BBIO Stock Holding History

DnB Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Buy	17,555 +714	+4%	+$50K	﹤0.01%	627
2026 Q1	$1.25M	Buy	16,841 +2,390	+17%	+$173K	﹤0.01%	624
2025 Q4	$1.11M	Buy	14,451 +4,028	+39%	+$264K	﹤0.01%	630
2025 Q3	$541K	Buy	+10,423	New	+$508K	﹤0.01%	670

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

DnB Asset Management's BBIO Position: Q2 2026 in Review

DnB Asset Management increased its BridgeBio Pharma (BBIO) stake by 4.2% in Q2 2026, buying an estimated $50K and bringing the position to 17,555 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #627.

DnB Asset Management first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

DnB Asset Management held 17,555 shares of BridgeBio Pharma worth $1.31M as of Q2 2026.
DnB Asset Management bought 714 BridgeBio Pharma shares in Q2 2026, an estimated $50K.
BridgeBio Pharma made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #627 holding.
DnB Asset Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.